Acessa™ Procedure for Symptomatic Uterine Fibroids Now Covered by Blue Cross Blue Shield of Michigan

Procedure provides women with a quick recovery, uterine-sparing alternative to hysterectomy

PR Newswire

LIVERMORE, Calif., July 7, 2015 /PRNewswire/ –  Halt Medical, Inc., the developer of the innovative minimally invasive Acessa™ treatment for symptomatic fibroids, today announced that Blue Cross Blue Shield, (BCBS) of Michigan now covers Acessa.  The largest private insurer in Michigan, Blue Cross Blue Shield covers over 2 million lives. BCBS of Michigan’s coverage policy can be found at

Acessa Procedure Logo 2013

“Millions of women suffer from heavy bleeding, pain and bloating due to fibroids, but prefer to avoid the risks and long recovery of a hysterectomy, so they just endure these debilitating symptoms,” said Russ DeLonzor, President and Chief Operating Officer.  “Now there is Acessa, a less invasive option that significantly reduces or eliminates these symptoms in a single outpatient procedure with a quick recovery time; most women return to normal activities in 3-5 days.”  BCBS of Michigan joins other major insurance companies Aetna, Health Care Services Corporation (a five state consortium of BCBS plans of Illinois, Montana, New Mexico, Oklahoma and Texas), Health Alliance Plan of MI, Coventry and others in offering coverage for Acessa.

About Uterine Fibroids

Fibroids are benign, non-cancerous tumors in a woman’s uterus that often appear during childbearing years.  Also called leiomyomas, fibroids are made up of muscle and connective tissue and may range in size from microscopic to larger than a grapefruit.  The rate at which they grow is unpredictable, and a woman may have more than one fibroid at a time.  While some fibroids are asymptomatic, others can be very painful and cause heavy bleeding, pressure on the bladder or rectum, a distended abdomen, and a lack of energy stemming from anemia.  The majority of American women will develop fibroids at some point in their lives. According to the National Institutes of Health (NIH), at least 70 percent of women in the U.S. will develop fibroids by age 50, and the prevalence is even higher among African American women.

About Acessa

Acessa is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy fibroids, and relieves symptoms without damaging or removing the uterus. After treatment, the fibroids are re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities.  Acessa is FDA-cleared for the treatment of symptomatic uterine fibroids. For more information please visit

About Halt Medical, Inc.

Halt Medical is a medical device innovator focused on establishing a new standard of care for women with symptomatic uterine fibroids. Along with the FDA clearance for treating fibroids, the company has received regulatory approval in the European Union, Canada, Mexico and Israel. Halt Medical is located in the San Francisco Bay Area.  For more information, please visit